Manzo Pharmaceuticals, Inc.
MNZO · OTC
12/31/2015 | 12/31/2014 | 12/31/2004 | 12/31/2003 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3 | $3 |
| % Growth | 267.5% | -100% | 2.2% | – |
| Cost of Goods Sold | $0 | $0 | $3 | $2 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | 39.4% | 100% | 0.7% | 25.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $0 | $0 | $3 | $4 |
| Operating Income | $0 | -$0 | -$3 | -$3 |
| % Margin | 39.4% | -44,856.4% | -104.2% | -108.1% |
| Other Income/Exp. Net | -$0 | -$1 | $3 | $3 |
| Pre-Tax Income | -$0 | -$1 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$4 | -$4 |
| % Margin | -1,799.6% | -180,493.8% | -135.2% | -131.6% |
| EPS | -0 | -0.003 | -1.2 | -1.2 |
| % Growth | 98.9% | 99.8% | 0% | – |
| EPS Diluted | -0 | -0.003 | -1.2 | -1.2 |
| Weighted Avg Shares Out | 1,160 | 340 | 3 | 3 |
| Weighted Avg Shares Out Dil | 1,160 | 340 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$3 | -$2 |
| % Margin | 39.4% | -81,886.5% | -93% | -76.5% |